companies innovating in obesity treatment glp-1 drugs 2025 The everything drugs: from weight loss to whole body medicines Potential Emerging Therapies in the

Description

Ganglion cell layer (GCL) volume was measured without pupil dilatation in both eyes of each patient by means of a 20 20 macular volume scan (centered on the macula with 512 A-scans and 25 B-scans aligned vertically with 16 averaged frames)

If they were forced to switch to a different medication due to the shortage, it is important to discuss their ongoing treatment plan with the relevant prescriber

Retatrutide: 40mg One sealed, pre-filled research device Fixed-volume research format Store refrigerated between 2C and 8C Do not freeze Research and development use only Why is Retatrutide studied

Market Statistics Key Takeaways By type of GLP-1 agonist drugs, the long-acting GLP-1 agonist segment dominated in 2025

Regulatory nods for Wegovy in Mexico and Brazil widen eligibility to millions of high-BMI adults, while cardiovascular-outcome data support use in secondary prevention